Bilici, AhmetÖlmez, Ömer FatihGürsoy, PınarÇubukçu, ErdemYıldız, ÖzcanSakın, AbdullahKorkmaz, TanerÇil, İbrahimÇakar, BeyhanMenekşe, SerkanDemir, TarıkAçıkgöz, ÖzgenHamdard, Jamshid2019-12-242019-12-242019Bilici, A., Ölmez, Ö. F., Gürsoy, P., Çubukçu, E., Yıldız, Ö., Sakın, A. ... Hamdard, J. (2019). Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology içinde (S664-S665. ss.). https://doi.org/10.1016/j.jtho.2019.08.14071556-13801556-0864https://doi.org/10.1016/j.jtho.2019.08.1407https://hdl.handle.net/20.500.12511/4653The significance of the presence of a systemic inflammatory response (SIR) in predicting survival has been demonstrated in patients with cancer. Moreover, neutrophil-to-lymphocyte ratio (NLR), lymphocyteratio (NLR), lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) have been also investigated in patients with both early and advanced non-small-cell lung cancer (NSCLC). However, determination of SIR predicting outcomes of patients who are likely to response to crizotinib in ALK-positive NSCLC patients has not been clearly demonstrated.eninfo:eu-repo/semantics/embargoedAccessSystemic InflammatoryALK-PositiveCellCrizotinibConference Object1410S664S66510.1016/j.jtho.2019.08.1407Q1